Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : A.I.M Users Group Bulletin Board -- Ignore unavailable to you. Want to Upgrade?

To: OldAIMGuy who wrote (4723)	5/18/1998 1:53:00 PM
From: Bruce A. Bowman	Read Replies (1) \| Respond to of 18928

Just read the news from the oncology seminar and it was great news about cancer prevention for women in the at-risk group for breast cancer. Eli LIlly and Zeneca Group Plc. Here's part of the the content: ------------- Monday May 18 12:04 PM EDT Two drugs may prevent breast cancer By Mark Egan LOS ANGELES (Reuters) - Women who have a high risk of breast cancer may have two drugs to choose from to prevent the disease -- one a cancer drug and one a drug originally designed for osteoporosis, researchers said Monday. They said both tamoxifen and raloxifene work to prevent breast cancer in certain woman. The news about raloxifene leaked out ahead of the annual meeting of the American Society of Clinical Oncology, but this was the first presentation of the details. Researchers said they were planning another trial that will pit the two drugs against each other to determine which of the two is more effective in preventing breast cancer. Dr. Steven Cummings of the University of California San Francisco said the osteoporosis drug raloxifene reduced the risk of developing breast cancer by 68 percent in post-menopausal women with osteoporosis. The trial of raloxifene, sold under the name Evista for treating osteoporosis by Eli Lilly & Co., began with the aim of determining the rate of fractures among women with osteoporosis and produced the breast cancer data as a bonus benefit. The study of almost 8,000 women found that raloxifene reduced the incidence of breast cancer in post-menopausal women by as much as 70 percent. Results indicated the drug did not increase the incidence of endometrial, or uterine, cancer. "These results for 33 months are very good news for women who are concerned about breast cancer and osteoporosis," Cummings told reporters. "Our trial is continuing so we can learn how well Evista prevents breast cancer over the longer term." Dr. Donald Wickerham of the National Surgical Adjuvant Breast and Bowel Project at Four Allegheny Center in Pittsburgh and colleagues did a separate study on tamoxifen. They found tamoxifen reduced the risk of breast cancer in 45 percent of women at high risk of the disease. "(This data) represents the first step in making the hope of breast cancer prevention a reality," Wickerham said. Wickerham said the comparison trial of the two drugs would begin this fall in post-menopausal women at high risk of breast cancer. Breast cancer is the most prevalent form of cancer in women, with about 180,000 cases diagnosed each year in the United States. It is expected that 43,500 women will die from the disease this year in the United States. Tamoxifen is marketed as a cancer drug under the name Nolvadex by Zeneca Group Plc. ... The article is filled with statistics, so you may want to go read the full story which is at: dailynews.yahoo.com